The emerging field of non-invasive neurotechnology is gaining interest from investors, as it offers a less risky and more cost-effective alternative to invasive brain treatments.
Neurovalens, a medtech startup focusing on wearable brain-stimulating technologies, has successfully raised $30.4 million funding to address various mental health and metabolic conditions.
Kerry Baldwin, from IQ Capital, emphasizes excitement in the sector by stating, 'The opportunity is massive at the moment,' reflecting investor potential in non-invasive neurotech.
While invasive neural interfaces like those from Neuralink attract significant funding, the much lower costs and risks associated with non-invasive methods create a compelling investment landscape.
Collection
[
|
...
]